Showing results (111-120 of 128) with videos related to
Sort By:
Pageof 13
Japanese Journal of Clinical Oncology|January 25, 2024
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING studyHisao Imai, Takashi Kijima, Koichi Azuma, et al.Cancer|February 6, 2020
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS studyTakayuki Takahama, Koichi Azuma, Mototsugu Shimokawa, et al.Journal for Immunotherapy of Cancer|July 11, 2023
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signaturesFeifei Wei, Koichi Azuma, Yoshiro Nakahara, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2011
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohortSeiji Yano, Tadaaki Yamada, Shinji Takeuchi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON StudyMelissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.Nature Communications|March 23, 2025
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLCKentaro Tanaka, Jun Sugisaka, Yoshimasa Shiraishi, et al.Lung Cancer (Amsterdam, Netherlands)|November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.Clinical Lung Cancer|November 19, 2023
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q)Shinji Nakamichi, Kaoru Kubota, Kotone Matsuyama, et al.Biomedicines|August 29, 2024
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint InhibitorsShun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, et al.The Lancet. Oncology|April 13, 2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, et al.Pageof 13